Here, we generated and characterized a novel CSP-targeting antibody, 1H11, evaluated its therapeutic efficacy as a monotherapy and in combination with chemotherapy, as well as investigated 1H11′s anticancer mechanism in ovarian cancer. This evidence concerns the gene DNAJC5 and ovarian cancer.